Merck’s LOE Mitigation Narrative Gains Traction, but Proof Points Remain Years Away

What happened

The Seeking Alpha article argues that Merck's aggressive M&A and R&D pipeline, including the Keytruda QLEX transition and Idvynso approval, are mitigating the Keytruda loss-of-exclusivity risk, pointing to management's $70B+ revenue target by mid-2030s. However, the DeepValue master report maintains a WAIT rating, highlighting that Keytruda still accounts for 49% of sales, the $2.5B FY2026 headwind from generics and IRA is real, and Gardasil's China pause remains unresolved with no restart visibility. The article's optimism is partly justified by the FDA approval of Idvynso and the successful QLEX transition, but these contributions are early and will take years to materially offset the 2028-2029 Keytruda cliff. Meanwhile, the master report's base case assumes FY2026 revenue near $66.3B, and the stock at $119 offers limited margin of safety given the concentrated earnings base and dated cliffs. The market appears to be partially pricing in the mitigation story, but investors should remain cautious until China Gardasil shipments resume and the FY2026 headwind bridge holds below $2.5B.

Implication

Long-term investors should not chase the stock based on the M&A and pipeline narrative alone. The thesis hinges on two observable checkpoints over the next 6-12 months: a Gardasil China restart signal and containment of the FY2026 headwind below $2.5B. Without these, the stock may re-test the attractive entry zone around $105. The article's $70B revenue target by mid-2030s is achievable only if recent acquisitions like Verona, Cidara, and Terns deliver commercial proof before 2028, which is far from guaranteed.

Thesis delta

The Seeking Alpha article introduces a more bullish narrative that LOE risks are mitigated by R&D and M&A, contrasting with the master report's cautious WAIT stance. This delta suggests the market may be repricing the stock to reflect a higher probability of a successful post-Keytruda transition. However, until the FY2026 headwind and Gardasil China issues are resolved, the master report's bearish scenarios remain plausible, and patience is warranted.